Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.

Abstract: A dentifrice composition and a method of making thereof are provided. The dentifrice composition includes an alginate, where the alginate is present in an amount from about 0.01 wt % to about 2 wt %, based on the total weight of the dentifrice composition; zinc compounds, wherein the zinc compounds include zinc oxide and zinc citrate trihydrate, wherein the zinc compounds are present in an amount from about 0.1 wt % to about 2 wt %, based on the total weight of the dentifrice composition; and an abrasive, wherein the abrasive includes calcium carbonate, wherein the abrasive is present in an amount from about 38 wt % to about 50 wt %, based on the total weight of the dentifrice composition.

Abstract: A consumer product including a personal care composition providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules.

Abstract: The present invention includes compositions and methods for treating a proliferative disorder comprising administering a therapeutically effective amount of an liposomal curcumin or curcuminoids to a human subject in need thereof in accordance with a dosing regimen comprising: at least one treatment cycle administering the therapeutically effective amount of the liposomal curcumin or curcuminoids once per week of at least 100 mg/m2 over 8 hours.

Abstract: This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure for indications such as, but not limited to, traumatic brain injury and stroke.

Abstract: Compositions are provided for removing nail polish that include a co-mixture that consists of C2-C3 monoalcohol, glycerin, and acetone. The glycerin and the C2-C3 monoalcohol are present in a glycerin to C2-C3 monoalcohol weight ratio of less than about 0.6. The composition further includes a cellulose polymer soluble in said C2-C3 monoalcohol. The concentration by weight of water in the composition is less than the concentration by weight of glycerin.

Abstract: A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.

Abstract: The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.

Abstract: An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 ?g/ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 ?g/ml in 50 minutes or less.

Abstract: Compositions that include: from 5 wt-% to 30 wt-% of one or more plant based oils based on the total weight of the composition; from 70 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; from 0.1 wt-% to 5 wt-% of one or more surfactants based on the total weight of the composition; and from 0.05 wt-% to 3 wt-% of a viscosity modifier, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and neem oil and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and neem oil.

Abstract: A consumer product including a fabric and home composition providing for multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules and method related thereto.

Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Abstract: A tooth paste composition comprising black cumin oil (Nigella sativa) and fluoride-doped bioactive glass, zinc oxide, and/or titanium oxide is disclosed.

Abstract: A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1? and 0.132?; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005? and 0.02? at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.

Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.

Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.

Abstract: An anti-microbial formulation for seed and crop application includes about 170 ppm hypochlorous acid; about 25 ppm hypochlorite ion; about 2.5 ppm ozone; about 2.5 ppm chlorine dioxide; between about 10 ppm and about 100,000 ppm alkyl polyglycoside; and a remainder of water. A method of manipulating the pH of the formulation and a method of treating seeds and crops with the formulation to restrict or eliminate microbial growth and proliferation is also described herein.